Establishment of a P-glycoprotein substrate screening model and its preliminary application

World Journal of Gastroenterology

Volumn 10, Issue 9, 2004, Pages 1365-1368

  Wang, Yi ^a   Cao, Jiang ^b   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; COMPLEMENTARY DNA; DNA FRAGMENT; DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PLASMID DNA; QUERCETIN; RESTRICTION ENDONUCLEASE; VERAPAMIL;

ARTICLE; BREAST CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SCREENING; DRUG SENSITIVITY; DRUG TRANSPORT; EXPRESSION VECTOR; GENE INSERTION; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MODEL; MOLECULAR CLONING; PROTEIN EXPRESSION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 4444248484     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i9.1365     Document Type: Article

References (19)

1. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002; 9: 1991-2002
2. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999; 36: 179-194
3. Hochman JH, Yamazaki M, Ohe T, Lin JH. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with p-glycoprotein. Curr Drug Metab 2002; 3: 257-273
4. Jovanovic SV, Simic MG. Antioxidants in nutrition. Ann N Y Acad Sci 2000; 899: 326-334
5. Wiseman H. The bioavailability of non-nutrient plant factors: dietary flavonoids and phyto-oestrogens. Proc Nutr Soc 1999; 58: 139-146
6. Graefe EU, Derendorf H, Veit M. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Ther 1999; 37: 219-233
7. Lamson DW, Brignall MS. Antioxidants and cancer 3: quercetin. Altern Med Rev 2000; 5: 196-208
8. 185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 1989; 162: 224-231
9. Becker K, Pan D, Whitley CB. Real-time quantitative polymerase chain reaction to assess gene transfer. Hum Gene Ther 1999; 10: 2559-2566
10. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull 1999; 22: 1355-1359
11. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-260
12. Shapiro AB, Ling V. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein. Eur J Biochem 1998; 254: 189-193
13. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398
14. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997; 94: 2031-2035
15. Kim RB, Fromn MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294
16. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999; 16: 1206-112
17. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999; 40: 301-306
18. Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Intl J Clin Pharmacol Ther 2000; 38: 161-167
19. Walgren RA, Walle UK, Walle T. Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol 1998; 55: 1721-1727